Results for tag: "Nonalcoholic Fatty Liver Disease"

Nonalcoholic Fatty Liver Disease (NAFLD) is a condition in which fat accumulates in the liver, leading to inflammation and scarring. It is the most common form of chronic liver disease in the world, and is closely linked to obesity, diabetes, and metabolic syndrome. NAFLD is a major concern in hepatology, as it can lead to cirrhosis and liver failure. It is also associated with an increased risk of cardiovascular disease. Treatment options for NAFLD include lifestyle modifications such as diet and exercise, as well as medications to reduce inflammation and improve insulin sensitivity. Several companies are involved in the NAFLD market, including Gilead Sciences, Intercept Pharmaceuticals, and Allergan. Gilead Sciences is developing a drug to treat NASH, while Intercept Pharmaceuticals is developing a drug to reduce liver fat. Allergan is developing a drug to reduce inflammation and improve insulin sensitivity. Show Less Read more